Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) EBIT: 2009-2024

Historic EBIT for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to -$5.1 million.

  • Anika Therapeutics' EBIT fell 3891.36% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$12.4 million, marking a year-over-year decrease of 161.08%. This contributed to the annual value of -$5.1 million for FY2024, which is 704.38% down from last year.
  • Per Anika Therapeutics' latest filing, its EBIT stood at -$5.1 million for FY2024, which was down 704.38% from $844,000 recorded in FY2023.
  • Anika Therapeutics' 5-year EBIT high stood at $3.7 million for FY2022, and its period low was -$28.3 million during FY2020.
  • Its 3-year average for EBIT is -$195,667, with a median of $844,000 in 2023.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 109.23% in 2021, then tumbled by 704.38% in 2024.
  • Anika Therapeutics' EBIT (Yearly) stood at -$28.3 million in 2020, then soared by 109.23% to $2.6 million in 2021, then skyrocketed by 40.34% to $3.7 million in 2022, then tumbled by 77.00% to $844,000 in 2023, then tumbled by 704.38% to -$5.1 million in 2024.